Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Florentine Cullinan is a biotechnology company focused on developing novel bispecific antibodies for the treatment of hematological malignancies. The company's lead program is a FLT3 x CD3 bispecific antibody designed to redirect T cells to eliminate FLT3-expressing leukemic cells in patients with acute myeloid leukemia (AML). Florentine Cullinan operates as a joint venture or specialized subsidiary within the Cullinan Oncology (now Cullinan Therapeutics) ecosystem, leveraging a hub-and-spoke model to advance targeted oncology therapies. The company aims to address high unmet needs in AML by utilizing a potent and selective immune-engaging modality.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Florentine Cullinan.